Phase I Trial of Everolimus Plus Sorafenib for Patients with Advanced Renal Cell Cancer
Authors:
- Amber L. FlahertyAFAmber L. Flaherty
- Mika StepankiwMSMika Stepankiw
- 1 March 2012
- journal article
- research article
- Published by Elsevier in Clinical Genitourinary Cancer
- Vol. 10 (1) , 26-31
Abstract
No abstract availableKeywords
This publication has 14 references indexed in Scilit:
- Sorafenib for Treatment of Renal Cell Carcinoma: Final Efficacy and Safety Results of the Phase III Treatment Approaches in Renal Cancer Global Evaluation TrialJournal of Clinical Oncology, 2009
- Targeting the mTOR Signaling Network for Cancer TherapyJournal of Clinical Oncology, 2009
- Role of RAF/MEK/ERK pathway, p‐STAT‐3 and Mcl‐1 in sorafenib activity in human pancreatic cancer cell linesJournal of Cellular Physiology, 2009
- mTOR Inhibitor RAD001 (Everolimus) Has Antiangiogenic/Vascular Properties Distinct from a VEGFR Tyrosine Kinase InhibitorClinical Cancer Research, 2009
- Mammalian target of rapamycin as a therapeutic target in oncologyExpert Opinion on Therapeutic Targets, 2008
- Hypoxia-inducible Factor 1α Is Regulated by the Mammalian Target of Rapamycin (mTOR) via an mTOR Signaling MotifJournal of Biological Chemistry, 2007
- Sorafenib in Advanced Clear-Cell Renal-Cell CarcinomaNew England Journal of Medicine, 2007
- mTOR, translation initiation and cancerOncogene, 2006
- Upstream of the mammalian target of rapamycin: do all roads pass through mTOR?Oncogene, 2006
- BAY 43-9006 Exhibits Broad Spectrum Oral Antitumor Activity and Targets the RAF/MEK/ERK Pathway and Receptor Tyrosine Kinases Involved in Tumor Progression and AngiogenesisCancer Research, 2004